Ads
related to: skyrizi for crohn's disease
Search results
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
Zacks via Yahoo Finance· 13 hours agoAbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease
Zacks via Yahoo Finance· 2 years agoThe FDA approval of AbbVie's (ABBV) Skyrizi for moderately to severely active Crohn's disease was...
AbbVie's (ABBV) Skyrizi Crohn's Disease Study Meets Goals
Zacks via Yahoo Finance· 9 months agoAbbVie's (ABBV) Skyrizi met both primary endpoints of non-inferiority for clinical remission at week...
Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication
Zacks via Yahoo Finance· 2 years agoThis week, Merck MRK offered to buy Imago Biosciences IMGO, which is developing drugs to treat bone...
European Authority Backs AbbVie's Crohn's Disease Candidate
Benzinga via Yahoo Finance· 2 years agoThe European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a...
FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq
Benzinga via Yahoo Finance· 1 year agoThe FDA approved AbbVie Inc's (NASDAQ: ABBV) Rinvoq (upadacitinib) for moderately to severely active...
AbbVie (ABBV) Gets CHMP Nod for Skyrizi in a Third Indication
Zacks via Yahoo Finance· 2 years agoThe CHMP recommends authorizing AbbVie's (SNY) Skyrizi as a treatment for Crohn's disease. The drug...
AbbVie's (ABBV) Skyrizi Meets Ulcerative Colitis Study Goals
Zacks via Yahoo Finance· 12 months agoAbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical...
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
Zacks via Yahoo Finance· 2 weeks agoShares of Eli Lilly LLY rose nearly 3% on Tuesday after it reported detailed one-year results from...
This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie
Motley Fool· 1 year agoAbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of...